

Available online at www.sciencerepository.org

Science Repository



Research Article

Identification of microRNAs as New Blood Biomarkers to Predict Breast Cancer Recurrence

Lauren Chen and Mithil Soni*

Department of Biological Science, University of South Carolina, Columbia, SC 29208

ARTICLE INFO

Article history:

Received: 27 April, 2019

Accepted: 8 May, 2019

Published: 20 May, 2019

Keywords:

microRNA
biomarker
recurrence
breast cancer

ABSTRACT

MicroRNAs (microRNAs) are short sequences of RNA (about 22 nucleotides) that are involved in the regulation of gene expression. Previous studies have suggested that a number of microRNAs are recognized as new biomarkers for cancers. The aim of this study is to identify specific microRNAs in serum, which may serve as potential diagnostic and prognostic biomarkers and therapeutic targets for breast cancer. Quantitative real-time PCR (qRT-PCR) array analyses of microRNAs in sera from four pairs of recurrent and nonrecurrent breast cancer patients were performed. Those differentially expressed microRNAs were verified in serum samples from 42 breast cancer patients. The prognostic values of the selected microRNAs were statistically analyzed, determined by the correlation between microRNA expression and tumor parameters. High serum levels of miR-134 and miR-483-5p were found to be associated with some aggressive tumor behaviors. Kaplan-Meier analysis of four upregulated microRNAs (miR-134, miR-483-5p, miR-493-3p and miR-139-3p) indicated that serum level of miR-134 can predict tumor recurrence in breast cancer patients after primary treatment. Identification of new blood biomarkers for prediction of recurrence may have a significant implication for breast cancer follow-up care and treatment.

© 2019 Mithil Soni. Hosting by Science Repository. All rights reserved.

Introduction

Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women [1]. Recent statistics suggest that about 1.3 million females develop breast cancer each year and about 465,000 of them succumb to the disease [2, 3]. Approximately 20-30% of early stage breast cancer cases will eventually experience recurrence. Previous studies have shown that the average rates of recurrence were 11-30% at 5 years and 20-36.8% at 10 years after completion of initial treatments. The 5-year progression-free survival (PFS) and overall survival (OS) were found to be 45% and 71% in the local recurrence group and 34% and 58% in the regional recurrence group. Therefore, there is an urgent need to identify novel biomarkers that can predict which patients will develop recurrence, either at diagnosis or before clinical manifestation of recurrence. Many factors that have been shown to be associated with breast cancer recurrence include age, tumor size, locality, lymph node

involvement, grade, estrogen receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor 2 (HER2) status [4]. These factors are determined in the primary tumor and are obtained through traditional tumor biopsy. However, a tissue sample cannot be continuously monitored during therapy and follow-up of cancer patients. MicroRNAs are small (about 21-25 nucleotides in length), non-coding RNA molecules. They regulate gene expression in a wide range of biological and pathological processes at the post-transcriptional level by binding to complementary sequences in the 3' untranslated region (UTR) of various target mRNAs, usually resulting in their silencing [5-8]. It has been well documented in the literature that microRNAs can control several key biological processes such as the cell cycle, apoptosis, differentiation, and stem cell regulation and have been found to be deregulated in cancer. MicroRNAs are released into blood circulation as a consequence of cell death or active secretion via exosomes. MicroRNA are easily accessible and reproducible, so they may have a good potential to serve as prognostic and predictive biomarkers for breast cancer.

*Correspondence to: Mithil Soni, Ph.D., Department of Biological Sciences, University of South Carolina, 715 Sumter Street, PSC621, Columbia, SC 29205; Tel: 803-777-1855; Fax: 803-777-4002; E-mail: msoni@email.sc.edu

A major advantage of blood-based biomarkers in the context of cancer recurrence is the fact that they can be monitored repeatedly, even after the primary tumor has been removed. Circulating microRNAs might be an ideal class of biomarkers for blood-based cancer detection because microRNA expression profiles are relatively cancer-specific. In addition, microRNAs are stable in cell-free plasma or serum, can be uniformly amplified and quantified, and thus are readily detected by quantitative real-time PCR. MicroRNAs may also play a pathogenic role in the disease process by acting as oncogenes or tumor suppressor genes. In recent years blood-based biomarkers such as microRNAs have been investigated for the diagnosis and prognosis of breast cancer [9-14]. In this study, we aimed to investigate if microRNA can be a biomarker for predicting breast cancer recurrence during the follow-up of breast cancer patients after initial treatment.

Materials and Methods

Serum samples

42 breast cancer patient serum samples were provided by the South Carolina Cancer Center tissue bank with the approved IRB protocol. All subjects were females breast cancer patients (Table S1). For each patient, blood samples were collected during follow-up visits after initial therapy of the primary breast cancer. Recurrent patients' samples were taken before diagnosis of the recurrence and the recurrence did not occur within the one year after initial therapy. Non-recurrent patients were included for plasma samples which had been taken after at least 1 year of follow-up after therapy and at least 12 months of known, recurrence-free follow-up after sample collection. The Clinicopathologic characteristics of patients are summarized in (Table 1).

RNA isolation

RNA from serum samples was isolated by Trizol LS reagent using manufacturer protocol. Briefly, 250ul of serum samples was used for RNA isolation. 750ul of Trizol reagent was added to serum, vortexed and incubated for 3-5 minutes at room temperature. 200ul of chloroform was then added, vortexed and incubated at room temperature for 3-5 minutes. Samples were then centrifuged at 4C for 15minutes at 12000g. Aqueous phase was collected in fresh tube. To precipitate RNA, the samples were treated with 500ul isopropyl alcohol and 5ul glycogen (5ng/ul) overnight at -20C. Following day, samples were centrifuged at 12000g, 4C for 10min. Precipitated RNA was then washed twice with 75% Ethanol and centrifuged at 7500g, 4C for 5 min. Finally, precipitated RNA was air-dried before resuspension with water.

Real-time PCR analysis of microRNA expression

For microRNA expression analysis, cDNA was synthesized as per manufacturer's recommendation. Purified RNA was first polyadenylated using Poly A polymerase (NEB#M0276). cDNA was then prepared using M-MLV Reverse Transcription kit (Invitrogen#28025013) and poly dT adapter primer. Qiagen Sybr green enzyme (Qiagen # 204141) was used to quantify microRNA expression. Real-Time PCR (ABI7900) instrument under the following conditions: hold at 95 °C for 10 minutes, then 45 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. The relative expression level of each microRNA expression was normalized

using miR-16-5p.

Statistical analysis

All results were confirmed in at least three independent experiments, and all quantitative data are presented as mean \pm SD or SEM as indicated. Student's t test or one-way ANOVA test was employed for analyzing quantitative variables. The patients were stratified based on the mean values of microRNA expression levels. The association between microRNA expression and the clinicopathologic parameters of the breast cancer patients was evaluated by the Fisher exact or Chi-square test. Survival curves were evaluated using Kaplan-Meier method and the differences between those survival curves were tested by log-rank test.

Table 1: Clinicopathologic characteristics of 42 breast cancer patients

| Characteristics | No. of Patients | Percentage |
|-------------------|-----------------|------------|
| Recurrence | | |
| Yes | 21 | 50.0% |
| No | 21 | 50.0% |
| Age at Diagnosis | | |
| < 55 | 24 | 57.1% |
| > 55 | 18 | 42.9% |
| Tumor Grade | | |
| I/II | 15 | 35.7% |
| III | 24 | 57.1% |
| NA | 3 | 7.1% |
| Best AJCC Staging | | |
| 0/1 | 4 | 9.5% |
| 2A | 3 | 7.1% |
| 2B | 32 | 76.2% |
| 3 | 1 | 2.4% |
| NA | 2 | 4.8% |
| Tumor Size (cm) | | |
| < 2.0 | 20 | 47.6% |
| \geq 2.0 | 19 | 45.2% |
| Unknown | 3 | 7.1% |
| Lymph Node Status | | |
| Negative | 13 | 31.0% |
| Positive | 26 | 61.9% |
| Unknown | 3 | 7.1% |
| ER Status | | |
| Negative | 8 | 19.0% |
| Positive | 28 | 66.7% |
| Unknown | 6 | 14.3% |
| PR Status | | |
| Negative | 18 | 42.9% |
| Positive | 18 | 42.9% |
| Unknown | 6 | 14.3% |
| HER2 Status | | |
| Negative | 19 | 45.20% |
| Positive | 11 | 26.20% |
| Unknown | 12 | 28.50% |

Table S1: Clinical characteristics of breast cancer patients

| ID | Age | Grade | Size (cm) | Lymph Node | Last Contact /Recurrence (Months) | Recurrence | ER Status | PR Status | HER2 Status |
|-------|-----|-------|-----------|------------|-----------------------------------|------------|-----------|-----------|-------------|
| 41245 | 72 | 3 | 0.4 | 17 | 46 | 1 | POSITIVE | NEGATIVE | NEGATIVE |
| 41247 | 60 | NA | N/A | N/A | 141 | 0 | N/A | N/A | N/A |
| 41265 | 53 | 2 | 2.6 | 1 | 10 | 1 | NEGATIVE | NEGATIVE | NEGATIVE |
| 41266 | 53 | 3 | 2.1 | 1 | 135 | 1 | POSITIVE | NEGATIVE | N/A |
| 41320 | 53 | 3 | 2.5 | 0 | 45 | 1 | N/A | N/A | NEGATIVE |
| 41326 | 60 | 2 | 1.7 | 1 | 41 | 0 | POSITIVE | NEGATIVE | POSITIVE |
| 41333 | 51 | 3 | 3 | 13 | 41 | 1 | POSITIVE | NEGATIVE | POSITIVE |
| 41334 | 33 | 3 | 1.2 | 1 | 10 | 1 | NEGATIVE | NEGATIVE | POSITIVE |
| 41351 | 47 | 2 | 3 | 1 | 121 | 1 | N/A | N/A | N/A |
| 41354 | 33 | 3 | 1.7 | 6 | 20 | 1 | POSITIVE | NEGATIVE | NEGATIVE |
| 41356 | 49 | 3 | 2.4 | 0 | 30 | 1 | NEGATIVE | NEGATIVE | NEGATIVE |
| 41359 | 36 | 3 | 2.5 | 1 | 6 | 1 | POSITIVE | POSITIVE | POSITIVE |
| 41371 | 42 | 3 | 1.1 | 1 | 76 | 0 | NEGATIVE | NEGATIVE | POSITIVE |
| 41373 | 48 | 3 | 2.1 | 6 | 32 | 1 | POSITIVE | NEGATIVE | NEGATIVE |
| 41375 | 61 | 2 | 0.2 | 98 | 50 | 0 | POSITIVE | NEGATIVE | NEGATIVE |
| 41377 | 59 | 1 | 1.7 | 0 | 27 | 0 | POSITIVE | POSITIVE | N/A |
| 41383 | 63 | 3 | 1.5 | 0 | 53 | 0 | POSITIVE | NEGATIVE | N/A |
| 41389 | 65 | 2 | 1.1 | 2 | 54 | 0 | NEGATIVE | POSITIVE | POSITIVE |
| 41441 | 35 | 3 | 1.4 | 0 | 31 | 0 | POSITIVE | NEGATIVE | NEGATIVE |
| 41446 | 68 | 3 | 2.5 | 13 | 96 | 0 | N/A | N/A | POSITIVE |
| 41450 | 54 | 3 | 8 | 95 | 42 | 1 | POSITIVE | NEGATIVE | NEGATIVE |
| 41460 | 47 | 1 | 0.9 | 1 | 38 | 0 | POSITIVE | POSITIVE | N/A |
| 41460 | 47 | 1 | 0.9 | 1 | 38 | 0 | POSITIVE | POSITIVE | N/A |
| 41469 | 38 | 3 | 0.4 | 0 | 16 | 1 | POSITIVE | POSITIVE | NEGATIVE |
| 41473 | 61 | 3 | 2 | 0 | 55 | 0 | POSITIVE | POSITIVE | N/A |
| 41475 | 57 | 3 | 3 | 23 | 20 | 1 | NEGATIVE | NEGATIVE | POSITIVE |
| 41476 | 56 | 2 | 0.3 | 1 | 63 | 1 | POSITIVE | POSITIVE | NEGATIVE |
| 41477 | 30 | 2 | 3 | 8 | 34 | 1 | POSITIVE | POSITIVE | N/A |
| 41481 | 31 | 3 | 2.5 | 0 | 25 | 0 | POSITIVE | POSITIVE | POSITIVE |
| 41481 | 31 | 3 | 2.5 | 0 | 25 | 0 | POSITIVE | POSITIVE | POSITIVE |
| 41489 | 64 | 2 | 1.2 | 2 | 40 | 0 | POSITIVE | POSITIVE | NEGATIVE |
| 41503 | 61 | N/A | N/A | N/A | 242 | 1 | N/A | N/A | N/A |
| 41509 | 37 | 1 | 2.2 | 2 | 180 | 0 | POSITIVE | POSITIVE | N/A |
| 41510 | 63 | 1 | 1.4 | 1 | 36 | 0 | POSITIVE | POSITIVE | NEGATIVE |
| 41525 | 53 | 1 | 1.1 | 0 | 34 | 0 | POSITIVE | POSITIVE | NEGATIVE |
| 41545 | 61 | 3 | 2.3 | 4 | 48 | 1 | POSITIVE | POSITIVE | NEGATIVE |
| 41552 | 60 | 3 | 9.5 | 8 | 101 | 0 | POSITIVE | NEGATIVE | POSITIVE |
| 41560 | 34 | 3 | 4.3 | 0 | 11 | 1 | NEGATIVE | NEGATIVE | NEGATIVE |
| 41561 | 53 | 3 | 5 | 95 | 23 | 1 | POSITIVE | POSITIVE | NEGATIVE |
| 41612 | 71 | 2 | 1.1 | 0 | 36 | 0 | POSITIVE | POSITIVE | NEGATIVE |
| 41625 | 54 | N/A | N/A | N/A | 268 | 1 | N/A | N/A | N/A |
| 41626 | 67 | 3 | 1.4 | 0 | 35 | 0 | NEGATIVE | NEGATIVE | NEGATIVE |

Results

microRNAs are differentially expressed in the serum of recurrent and non-recurrent breast cancer patients

To determine whether the microRNA profiles of recurrent and non-recurrent breast cancer serum samples may differ, total RNA was isolated from four pairs of recurrent and non-recurrent patient serum and converted into cDNA for microRNA screening. The cDNA quality was first examined by PCR analysis of expression of two high abundant

microRNAs: miR99 and miR16. As shown in Figure1, two microRNA could be specifically amplified from two serum cDNAs. We used miR-16 as internal control for our analysis [15]. In our previous studies, we did RT-PCR array analysis of microRNA expression in breast cancer cells and studied the role of miR-489 in breast cancer cells [16-18]. In these studies, we screened about 350 microRNAs by RT-PCR analysis in breast cancer cells and found that about 60 of them are commonly differentially expressed in breast cancer cells [16]. Most these differentially expressed miRNAs are not necessarily secreted. We then compared our list with the exosomal microRNAs derived from breast

cancer cells and circulating microRNA found in cancer sera samples [19-21], and selected 22 cancer related microRNAs in these four recurrent and four non-recurrent patient samples. The expression of three microRNAs (miR-96-3p, miR-340-5p and miR-373-3p) was not detectable in any of the serum samples. Seven out of 22 selected microRNAs were differently expressed in recurrent and non-recurrent

samples based on the p value cutoff of 0.05 (Table 2). Three microRNAs (miR-146, miR-200a and miR141) were downregulated and four microRNAs (miR-134, miR-139-3p, miR-483-5p and miR-493-3p) were upregulated in recurrent samples compared to non-recurrent samples. We reasoned that the upregulated microRNA may be secreted by the recurrent tumor cells and potentially serve as prognostic biomarkers.

Table 2: Real-time PCR analysis of microRNA expression in serum samples from 4 pairs of recurrent and non-recurrent breast cancer patients.

| miR Name | Non-recurrent Patients (Δ Ct) | | | | Recurrent patients (Δ Ct) ^a | | | | Fold Change | T-test (p value) |
|-------------|---------------------------------------|---------|---------|---------|--|---------|---------|---------|-------------|------------------|
| | No. 375 | No. 377 | No. 460 | No. 481 | No.265 | No. 333 | No. 245 | No. 266 | | |
| miR-146a-5p | 9.2 | 7.4 | 7.9 | 9.2 | 24.2 | 24.4 | 24.9 | 25.0 | 0.00 | 0.000 |
| miR-139-3p | 14.3 | 13.2 | 15.6 | 15.9 | 10.2 | 12.0 | 10.4 | 9.1 | 20.45 | 0.008 |
| miR-134 | 11.3 | 17.3 | 14.0 | 15.2 | 7.1 | 10.7 | 11.0 | 8.9 | 33.54 | 0.017 |
| miR-493-3p | 16.3 | 14.2 | 15.7 | 14.5 | 12.8 | 13.3 | 9.8 | 7.8 | 19.22 | 0.021 |
| miR-483-5p | 10.0 | 9.9 | 10.3 | 11.8 | 7.8 | 9.6 | 8.5 | 8.9 | 3.39 | 0.023 |
| miR-141 | 24.8 | 13.5 | 16.0 | 15.2 | 25.0 | 24.4 | 24.9 | 25.1 | 0.01 | 0.026 |
| miR-200a | 18.2 | 25.0 | 16.1 | 16.9 | 24.3 | 24.7 | 24.8 | 23.9 | 0.02 | 0.026 |
| miR-138-5p | 17.5 | 17.0 | 22.2 | 18.8 | 13.0 | 14.5 | 18.3 | 13.6 | 16.41 | 0.052 |
| miR-181b-5p | 12.4 | 11.5 | 12.5 | 14.7 | 13.9 | 15.1 | 24.7 | 24.9 | 0.01 | 0.067 |
| miR-424-5p | 6.3 | 4.8 | 6.3 | 7.1 | 9.2 | 6.1 | 7.5 | 9.8 | 0.25 | 0.087 |
| miR-199b-5p | 13.3 | 25.0 | 12.8 | 15.2 | 25.0 | 14.5 | 23.6 | 24.6 | 0.02 | 0.184 |
| miR-324-3p | 8.1 | 8.7 | 7.3 | 8.6 | 6.8 | 8.8 | 6.9 | 5.9 | 2.05 | 0.187 |
| miR-200b-3p | 14.7 | 13.4 | 14.4 | 14.7 | 6.9 | 25.3 | 24.6 | 24.7 | 0.01 | 0.222 |
| miR-182-5p | 13.7 | 25.0 | 13.9 | 14.7 | 24.3 | 11.7 | 25.3 | 24.6 | 0.03 | 0.303 |
| miR-142-3p | 9.2 | 9.3 | 10.5 | 12.6 | 14.4 | 10.7 | 10.3 | 10.9 | 0.44 | 0.376 |
| miR-188-5p | 12.9 | 24.8 | 14.0 | 13.5 | 15.3 | 13.3 | 12.3 | 15.2 | 5.04 | 0.463 |
| miR-105-5p | 24.6 | 24.7 | 24.8 | 20.0 | 11.2 | 24.5 | 24.3 | 24.7 | 4.53 | 0.574 |
| miR-127-3p | 12.6 | 16.6 | 17.2 | 15.1 | 12.7 | 10.2 | 25.0 | 6.4 | 3.49 | 0.679 |
| miR-486-5p | -1.2 | -1.9 | -0.4 | -0.3 | 0.5 | -0.6 | -0.5 | -2.6 | 0.89 | 0.819 |

Correlation of serum microRNA levels with clinical characteristics

We decided to examine the expression levels of four upregulated microRNAs including miR-134, miR-483-5p, miR-493 and miR-139-3p in the sera of 42 breast cancer patients (Table 1 and 3). Based on the expression levels of each microRNA, we stratify the patients into two groups and performed Chi-square test to analyze the associations of these microRNA with various primary tumor parameters, including tumor grade, tumor size, nodal status, ER status, PR status and HER2 status. We found that tumors with high levels of miR-134 were more likely to spread into lymph node (p = 0.0362) (Table 3). The miR-483-5p expression was positively associated with tumor size (p= 0.0436) but negatively associated with PR expression status (p = 0.0256) (Table 3). High levels of miR-493 expression were weakly associated with positive PR status. Other microRNA did not show significant association with the primary parameters, likely due to the limited sample size.

miR-134 expression in patient serum predicts breast cancer recurrence

To evaluate if any of these microRNAs can predict breast cancer recurrence, we performed a Kaplan-Meier analysis (Figure 2A-D). High expression of miR-134 and miR-483-5p in patient serum tend to be associated with high risk of impending breast cancer recurrence (Figure 2C-D). The association of recurrence and miR-134 remained significant

(P = 0.0226) (Figure 2D). Taken together, these observations suggested that selected microRNA can be very promising biomarkers to predict the breast cancer recurrence.



Figure 1: Representative image of PCR amplification of miR-99 and miR-16 from sera of two breast cancer patients. RNA was extracted from two individual patients samples. This experiments were repeated once and similar results were obtained.




Figure 2: Kaplan–Meier analysis of recurrence-free survival (RFS) for breast cancer patients. The patient groups are stratified based on the expression levels of miR-139-3p (A), miR-493-3p (B), miR-483-5p (C) and miR-134 (D) in patients’ sera.

Table 3. The association of miR-134, miR-483-5p, miR-139-3p and miR-493-3p with clinical parameters

| Characteristics | miR-134 | | Chi-square (p value) | miR-483-5p | | Chi-square (p value) | miR-139-3p | | Chi-square (p value) | miR-493-3p | | Chi-square (p value) |
|---------------------|-----------|------------|----------------------|------------|------------|----------------------|------------|------------|----------------------|------------|------------|----------------------|
| | Low n (%) | High n (%) | | Low n (%) | High n (%) | | Low n (%) | High n (%) | | Low n (%) | High n (%) | |
| HER2 Status | | | 0.4473 | | | 0.4786 | | | 0.2557 | | | 0.2789 |
| Negative | 6 (54.5) | 13 (66.7) | | 12 (60.0) | 8 (72.7) | | 11 (73.3) | 8 (53.3) | | 9 (75.0) | 10 (55.6) | |
| Positive | 5 (45.5) | 6 (31.6) | | 8 (40.0) | 3 (27.3) | | 4 (26.7) | 7 (46.7) | | 3 (25.0) | 8 (44.4) | |
| ER Status | | | 0.3609 | | | 0.8423 | | | 0.4648 | | | 0.1203 |
| Negative | 2 (14.3) | 6 (27.3) | | 6 (23.1) | 2 (20.0) | | 4 (28.6) | 4 (18.2) | | 5 (35.7) | 3 (13.6) | |
| Positive | 12 (85.7) | 16 (63.7) | | 20 (76.9) | 8 (80.0) | | 10 (71.4) | 18 (81.8) | | 9 (64.3) | 19 (86.4) | |
| PR Status | | | 0.1715 | | | 0.0256 | | | 0.4941 | | | 0.0402 |
| Negative | 5 (35.7) | 13 (59.1) | | 10 (38.5) | 8 (80.0) | | 8 (57.1) | 10 (45.5) | | 10 (71.4) | 8 (36.4) | |
| Positive | 9 (64.2) | 9 (40.9) | | 16 (61.5) | 2 (20.0) | | 6 (42.9) | 12 (54.5) | | 4(28.6) | 14 (63.6) | |
| Tumor Size | | | 0.305 | | | 0.0436 | | | 0.749 | | | 0.2718 |
| < 2 cm | 8 (61.5) | 11 (44.0) | | 15 (62.5) | 4 (28.6) | | 9 (52.9) | 11 (47.8) | | 9 (64.3) | 11(45.8) | |
| ≥ 2 cm | 5 (39.8) | 14 (56.0) | | 9 (37.5) | 10 (71.4) | | 8 (47.1) | 12 (52.2) | | 5 (36.7) | 13 (54.2) | |
| Lymph Status | | | 0.0362 | | | 0.6369 | | | 0.7401 | | | 0.6369 |
| Negative | 8 (53.3) | 5 (20.8) | | 9 (36.0) | 4 (28.6) | | 5 (29.4) | 8 (36.4) | | 4 (28.5) | 9 (36.0) | |
| Positive | 7 (46.7) | 19 (79.2) | | 16 (64.0) | 10 (71.4) | | 12 (70.6) | 14 (63.6) | | 10 (71.5) | 16 (64.0) | |
| Tumor Grade | | | 0.6279 | | | 0.1018 | | | 0.3072 | | | 0.3421 |
| I/II | 6 (42.9) | 9 (36.0) | | 12 (48.0) | 3 (21.4) | | 5 (29.4) | 10 (45.5) | | 4 (28.5) | 11 (44.0) | |
| III | 8 (57.1) | 16 (64.0) | | 13 (52.0) | 11 (78.6) | | 12 (70.6) | 12 (54.5) | | 10 (61.5) | 14 (66.0) | |

Discussion

Circulating miRNAs are an emerging field of cancer biomarker research [10, 11, 15, 22, 23]. Global and focused screening approaches have been used to identify circulating miRNAs, which can serve as the biomarker for predict cancer progression. In this study, we demonstrated that circulating miRNA can be used to predict breast cancer recurrence. By screening circulating miRNA expression profiles in sera samples from patients after initial treatment, we identified four miRNAs (miR-134, miR-483-5p, miR-493-3p and miR-139-3p) that were consistently upregulated in recurrent patients compared to non-recurrent patients. Further statistical analysis revealed that miR-134 was directly correlated with recurrence. High miR-134 expression was associated with lymph node metastasis and predicted higher recurrence rate. miR-134 has been previously reported to be present in serum and reported to be secreted through exosomes [24]. Previous study has found increased miR-134 in serum of pancreatic cancer [25]. Another study showed that miR-134 might be an emerging diagnostic biomarker in early stage of acute myocardial infarction because its expression was markedly increased in patients' plasma [26]. In another study, miR-134 expression was downregulated in patients' tissue and associated with the size of tumor and terminal pathologic grade and advancement of tumor development in gastrointestinal stromal cancer. Decreased miR-134 expression contributed to lower total survival as well [27]. miR-134 expression in serum of breast cancer patients has not been reported yet. We found that it was highly expressed in serum of recurrent patients when compared to non-recurrent patients. In contrast, miR-134 has been previously shown as a tumor suppressor microRNA in breast cancer and shown to suppress proliferation, migration and invasion [28]. It is possible that cancer cells may expel miR-134 to prevent its growth suppressive effect. Further study comparing miR-134 expression in cancerous tissue and serum of same patient side by side might reveal more insight on this complex observation. Nonetheless, our study shows that miR-134 can be used as a potential biomarker to predict recurrence in breast cancer patient. MiR-483-5p has been shown to be dysregulated in adrenocortical carcinoma and indeed, can be useful diagnostic and prognostic marker [29]. It was highly expressed in adrenocortical tumor tissue as well as in serum of malignant tumors compared to benign. Consistent with this result, our study also found strong positive correlation of miR-483-5p with tumor size. Another study also reported increased serum miR-483-5p levels in oral squamous cell carcinoma. miR-483-5p has been shown largely to function as oncogenic microRNA [30]. Interestingly, consistent with our results, a recent study comparing serum level of miR-483-5p showed increased expression level in serum of breast cancer patients when compared to serum of healthy individuals [31]. Several other microRNAs including miR-139-3p and miR-483-5p were observed differentially present in serum of breast cancer patients. Consistently, miR-139-3p has been shown to be present in serum. Interestingly, study exploring miR-139-3p in breast cancer found that its downregulation in cancer tissue is indicative of aggressive cancer. However, study could not find significant difference in serum level of miR-139-3p [32]. Our study did detect miR-139 in the breast cancer patient serum but seemed not to be associated any breast cancer pathological parameters including recurrence.

The major pitfall of this study is the limited sample size, we suggest expanding this study in a large cohort of patients to further confirm the

potential application of selected microRNAs as diagnostic markers. Increasing sample size can also help minimizing the problems associated with a relatively large variation among samples which was generated at least partially due to data normalization using miR-16 as the internal control. The common issue for quantification of circulating miRNA is the lack of a solid and common normalization strategy to account for inter-individual or intergroup variability [33]. Most of the results were obtained by qPCR, using different reference genes for normalization such as miR-16, miR-1207, miR-484, and miR-24 [15, 19, 20, 34-36]. MiR-16 is most frequently used as endogenous control for data normalization of circulating miRNAs, because this miRNA is highly expressed in plasma or serum, and has been described as being relatively invariant across diverse blood samples of breast cancer patients [15, 19, 21, 37]. Our data also showed that miR-16 is most stably expressed in our samples. We therefore selected miR-16 as the internal control for our qRT-PCR analysis. Further studies with a large samples size and different normalization methods may help to clarify this issue.

In summary, this study identified microRNA with differential serum levels in recurrent and non-recurrent breast cancer patients. Assessing their levels in serum of breast cancer patient might help predicting patients who are predisposed to recurrence and who require more aggressive therapy and close monitoring after primary treatment.

Acknowledgement

I thank the South Carolina Cancer Center Tissue Bank for providing us the patient serum samples. This study was partially supported by a SPARC grant to MS.

REFERENCES

- Hutchinson L (2010) Breast cancer: challenges, controversies, breakthroughs. *Nat Rev Clin Oncol* 7: 669-70. [[Crossref](#)]
- Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D et al. (2012) The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. *Expert Opin Ther Targets* 2: S103-S109. [[Crossref](#)]
- Herranz M, Ruibal A (2012) Optical imaging in breast cancer diagnosis: the next evolution. *J Oncol* 2012: 863747. [[Crossref](#)]
- Cheng J, Cuk K, Heil J, Golatta M, Schott S et al. Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. *Oncotarget* 8: 54537-54547. [[Crossref](#)]
- Ambros V (2001) microRNAs: tiny regulators with great potential. *Cell* 107: 823-826. [[Crossref](#)]
- Ambros V (2003) MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. *Cell* 113: 673-676. [[Crossref](#)]
- Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. *Cell* 136: 215-233. [[Crossref](#)]
- Bartel DP, Chen CZ (2004) Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. *Nat Rev Genet* 5: 396-400. [[Crossref](#)]
- Andorfer CA, Necela BM, Thompson EA, Perez EA (2011) MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. *Trends Mol Med* 17: 313-319. [[Crossref](#)]

10. Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W et al. (2017) Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. *Cell Death Dis* 8: e3045. [[Crossref](#)]
11. He Y, Deng F, Yang S, Wang D, Chen X et al. (2017) Exosomal microRNA: a novel biomarker for breast cancer. *Biomark Med* 12: 177-188. [[Crossref](#)]
12. Lehmann U (2014) Aberrant DNA methylation of microRNA genes in human breast cancer - a critical appraisal. *Cell Tissue Res* 356: 657-64. [[Crossref](#)]
13. Shi M, Guo N (2009) MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. *Cancer Treat Rev* 35: 328-34. [[Crossref](#)]
14. Wang SE, Lin RJ (2013) MicroRNA and HER2-overexpressing Cancer. *Microna* 2: 137-147. [[Crossref](#)]
15. Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). *Methods* 50: 298-301. [[Crossref](#)]
16. Patel Y, Shah N, Lee JS, Markoutsas E, Jie C et al. (2016) A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. *Oncotarget* 7: 18295-18308. [[Crossref](#)]
17. Patel Y, Soni M, Awgulewitsch A, Kern MJ, Liu S et al. (2018) Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis. *Oncogene* 38: 445-453. [[Crossref](#)]
18. Soni M, Patel Y, Markoutsas E, Jie C, Liu S et al. (2018) Autophagy, Cell Viability and Chemoresistance Are Regulated By miR-489 in Breast Cancer. *Mol Cancer Res* 16: 1348-1360. [[Crossref](#)]
19. Zhou W, Fong MY, Min Y, Somlo G, Liu L et al. (2014) Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. *Cancer Cell* 25: 501-515. [[Crossref](#)]
20. Eichelsler C, Stuckrath I, Muller V, Milde-Langosch K, Wikman H et al. (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. *Oncotarget* 5: 9650-9663. [[Crossref](#)]
21. Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB et al. (2014) MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. *BMC Cancer* 14: 200. [[Crossref](#)]
22. Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G et al. (2006) Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. *Electrophoresis* 27: 1641-1650. [[Crossref](#)]
23. Chen M, Calin GA, Meng QH (2014) Circulating microRNAs as Promising Tumor Biomarkers. *Adv Clin Chem* 67: 189-214. [[Crossref](#)]
24. Sempere LF, Keto J, Fabbri M (2017) Exosomal MicroRNAs in Breast Cancer towards Diagnostic and Therapeutic Applications. *Cancers* 9. [[Crossref](#)]
25. Li A, Yu J, Kim H, Wolfgang CL, Canto MI et al. (2013) MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. *Clin Cancer Res* 19: 3600-3610. [[Crossref](#)]
26. He F, Lv P, Zhao X, Wang X, Ma X et al. (2014) Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. *Mol Cell Biochem* 394: 137-144. [[Crossref](#)]
27. Haller F, von Heydebreck A, Zhang JD, Gunawan B, Langer C et al. (2010) Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. *J Pathol* 220: 71-86. [[Crossref](#)]
28. Su X, Zhang L, Li H, Cheng P, Zhu Y et al. (2017) MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion. *Oncol Lett* 13: 1932-1938. [[Crossref](#)]
29. Chabre O, Libe R, Assie G, Barreau O, Bertherat J et al. (2013) Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. *Endocr Relat Cancer* 20: 579-594. [[Crossref](#)]
30. Song Q, Xu Y, Yang C, Chen Z, Jia C et al. (2014) miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. *Cancer Res* 74: 3031-3042. [[Crossref](#)]
31. Rimi Hamam, Arwa M. Ali, Khalid A. Alsaleh, Moustapha Kassem, Musaed Alfayez et al. (2016) microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. *Sci Rep* 6: 25997. [[Crossref](#)]
32. Dai H, Gallagher D, Schmitt S, Pessetto ZY, Fan F et al. (2017) Role of miR-139 as a surrogate marker for tumor aggression in breast cancer. *Hum Pathol* 61: 68-77. [[Crossref](#)]
33. Schwarzenbach H, da Silva AM, Calin G, Pantel K (2015) Data Normalization Strategies for MicroRNA Quantification. *Clin Chem* 61: 1333-1342. [[Crossref](#)]
34. Xiang M, Zeng Y, Yang R, Xu H, Chen Z et al. (2014) U6 is not a suitable endogenous control for the quantification of circulating microRNAs. *Biochem Biophys Res Commun* 454: 210-214. [[Crossref](#)]
35. Stuckrath I, Rack B, Janni W, Jager B, Pantel K et al. (2015) Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. *Oncotarget* 6: 13387-13401. [[Crossref](#)]
36. Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A (2015) Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. *Br J Cancer* 112: 1751-1759. [[Crossref](#)]
37. Yan W, Wu X, Zhou W, Fong MY, Cao M et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. *Nat Cell Biol* 20: 597-609. [[Crossref](#)]